• 877 Citations
  • 13 h-Index
20112019
If you made any changes in Pure these will be visible here soon.

Personal profile

Public Profile

David Yeung is a postdoctoral research fellow with the Precision Medicine Theme at the SHAMRI. He also has positions with the Royal Adelaide Hospital and SA Pathology as a practicing haematologist and haemato-pathologist, and has affiliations with both the University of Adelaide and the University of South Australia. He had training in clinical and laboratory haematology in Sydney before completing his PhD in Adelaide. His focus is on improving outcomes for patients with chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL). Along with Prof Tim Hughes, David leads several national CML clinical trials, with the aim of optimising the use to tyrosine kinase inhibitors leading to improved efficacy and reduced toxicity. Innovative correlative study research projects attached to this clinical trials allow further understand of the biology underlying resistant cases. David also has project with Prof Deb White of the Cancer Theme, who heads the national effort in understanding and improving outcomes in high risk ALL. He has co-authored 24 publications in peer reviewed journals and 2 book chapters in postgraduate text books.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2011 2019

Compound mutations in CML—imaginary bogeyman or real arch-nemesis?

Yeung, D., 1 Jan 2019, In : Leukemia Research.

Research output: Contribution to journalEditorial

Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission

Shanmuganathan, N., Braley, J. A., Yong, A., Hiwase, D. K., Yeung, D., Ross, D. M., Hughes, T. & Branford, S., 4 Jul 2019, In : Blood. 134, 1, p. 85-89 5 p.

Research output: Contribution to journalLetter

1 Citation (Scopus)

The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia

Minson, A. G., Cummins, K., Fox, L., Costello, B., Yeung, D., Cleary, R., Forsyth, C., Tatarczuch, M., Burbury, K., Motorna, O., Shortt, J., Fleming, S., McQuillan, A., Schwarer, A., Harrup, R., Holmes, A., Ratnasingam, S., Chan, K. L., Hsu, W. H., Ashraf, A. & 2 othersPutt, F. & Grigg, A., 9 Apr 2019, In : Blood Advances. 3, 7, p. 1084-1091 8 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J. M., Nicola, M., Saunders, V. A., Braley, J., White, D. L., Yeung, D. T., Branford, S., Hughes, T. P. & Ross, D. M., 30 Nov 2018, In : Haematologica. 103, 12, p. 2026-2032 7 p.

Research output: Contribution to journalArticle

Open Access

Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study

Hiwase, D., Tan, P., D'Rozario, J., Taper, J., Powell, A., Irving, I., Wright, M., Branford, S., Yeung, D. T., Anderson, L., Gervasio, O., Levetan, C., Roberts, W., Solterbeck, A., Traficante, R. & Hughes, T., 1 Apr 2018, In : Leukemia Research. 67, p. 109-115 7 p.

Research output: Contribution to journalArticle